LUND, Sweden, June 27, 2022 /PRNewswire/ -- Immunovia will present PanFAM-1 results today, June 27, 2022 at 13:00 pm CET. Analysts, investors and media are invited to a webcast and teleconference. The presentation slides will be available at www.immunovia.com. See also press release published: https://investor.immunovia.com/panfam-1-results-partly-inconclusive/
Philipp Matieu, CEO and President, Thomas King, Medical Director, and Jeff Borcherding, CEO US operations, will present. The presentation will be held in English and be followed by a Q&A session. You are welcome to join via webcast or phone, see details below.
Telephone numbers and webcast
Ring any of the numbers below to participate via telephone. Please dial in a few minutes before the presentation starts.
Sweden: +46 8 50 51 00 31United Kingdom: +44 207 107 06 13United States: +1 631 570 56 13
Link to the webcast: https://creo-live.creomediamanager.com/806a27cb-a49a-4fa9-b7e7-3ac9fd7a4795
To ask questions, it is necessary to dial in. A recording of the presentation will be available on Immunovia's website.
For more information, please contact:Tobias Bülow Senior Director Investor Relations and Corporate Communicationstobias.firstname.lastname@example.org+46 736 36 35 74
The information was submitted for publication on June 27, 2022, at 09:00 am CET.
Immunovia AB is a diagnostic company with the vision to revolutionize blood-based diagnostics and increase survival rates for patients with cancer.
Our first product, IMMray PanCan-d is the only blood test currently available specifically for the early detection of pancreatic cancer. The test has unmatched clinical performance. Commercialization of IMMray PanCan-d started in August 2021 in the USA and IMMray PanCan-d is offered as a laboratory developed test (LDT) exclusively through Immunovia, Inc. For more information see: www.immunoviainc.com.
Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups globally to make this test available to all high-risk pancreatic cancer groups.
The USA, the first market in which IMMray PanCan-d is commercially available, is the world's largest market for the detection of pancreatic cancer with an estimated value of more than USD 4 billion annually.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download: